

Progenics Pharmaceuticals, Inc. (PGNX) - Financial and Strategic SWOT Analysis Review

URL:	https://marketpublishers.com/r/P777AF6C943EN.html
Date:	July 19, 2016
Pages:	53
Price:	US\$ 125.00
ID:	P777AF6C943EN

Progenics Pharmaceuticals, Inc. (PGNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Progenics Pharmaceuticals, Inc. (Progenics) is a late-stage biopharmaceutical company that focuses on developing medicines and products for the treatment of cancer and related conditions. Its only commercial product, Relistor, is used for the treatment of opioid-induced constipation. The company's pipeline comprises therapeutic agents that are designed to target cancer; PSMA-targeted imaging agents for prostate cancer that enable clinicians and patients to visualize and manage their disease; and a phase III candidate for the treatment of HIV. Progenics also offers bone scan index product, namely, EXINI Bone BSI tool which reads bone scans and produce automated bone scan index quantification. Its EXINI Bone BSI tool is approved for use in Europe, Japan and the US. Through a licensing agreement with Salix Pharmaceuticals the company markets Relistor outside the US except Japan. Progenics is headquartered in Tarrytown, New York, the US.

Progenics Pharmaceuticals, Inc. Key Recent Developments

Jun 13, 2016: Progenics Pharmaceuticals Announces Presentations on its Prostate Cancer Imaging Programs at SNMMI 2016

Jun 09, 2016: Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors

May 05, 2016: Progenics Pharmaceuticals Announces First Quarter 2016 Financial and Business Results

Mar 11, 2016: Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2015 Financial and Business Results

Jan 07, 2016: Progenics Pharmaceuticals Commences Pivotal Phase 3 Study of PSMA Targeted Imaging Agent 1404 for Prostate Cancer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Content

SECTION 1 - ABOUT THE COMPANY

Progenics Pharmaceuticals, Inc. - Key Facts

Progenics Pharmaceuticals, Inc. - Key Employees

Progenics Pharmaceuticals, Inc. - Key Employee Biographies

Progenics Pharmaceuticals, Inc. - Major Products and Services

Progenics Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data

Progenics Pharmaceuticals, Inc., Pipeline Products by Therapy Area

Progenics Pharmaceuticals, Inc., Pipeline Products by Development Phase

Progenics Pharmaceuticals, Inc. - History

Progenics Pharmaceuticals, Inc. - Company Statement

Progenics Pharmaceuticals, Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Progenics Pharmaceuticals, Inc. - Business Description
Progenics Pharmaceuticals, Inc. - Corporate Strategy
Progenics Pharmaceuticals, Inc. - SWOT Analysis
SWOT Analysis - Overview
Progenics Pharmaceuticals, Inc. - Strengths
Strength - Research and Development Activities
Strength - Lead Product - Relistor
Progenics Pharmaceuticals, Inc. - Weaknesses
Weakness - Declining Working Capital
Progenics Pharmaceuticals, Inc. - Opportunities
Opportunity - Market Potential – Oncology
Opportunity - Pipeline Products
Opportunity - Orphan Drug Designation
Progenics Pharmaceuticals, Inc. - Threats
Threat - Stringent Government Regulations
Threat - Influx of Generics
Threat - Lack of Manufacturing Facilities
Progenics Pharmaceuticals, Inc. - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Progenics Pharmaceuticals, Inc., Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jun 13, 2016: Progenics Pharmaceuticals Announces Presentations on its Prostate Cancer Imaging Programs at SNMMI 2016
Jun 09, 2016: Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
May 05, 2016: Progenics Pharmaceuticals Announces First Quarter 2016 Financial and Business Results
Mar 11, 2016: Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2015 Financial and Business Results
Jan 07, 2016: Progenics Pharmaceuticals Commences Pivotal Phase 3 Study of PSMA Targeted Imaging Agent 1404 for Prostate Cancer
Nov 16, 2015: Progenics Pharmaceuticals Announces the Appointment of Patrick Fabbio as Chief Financial Officer
Nov 09, 2015: Progenics Pharmaceuticals Announces Third Quarter 2015 Financial Results
Oct 12, 2015: Data From Phase 2 Study of Progenics’ 1404 Imaging Agent Presented at EANM Congress 2015
Aug 06, 2015: Progenics Pharmaceuticals Announces Second Quarter 2015 Financial Results
May 06, 2015: Progenics Pharmaceuticals Announces First Quarter 2015 Financial Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Progenics Pharmaceuticals, Inc., Key Facts
Progenics Pharmaceuticals, Inc., Key Employees
Progenics Pharmaceuticals, Inc., Key Employee Biographies
Progenics Pharmaceuticals, Inc., Major Products and Services
Progenics Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area
Progenics Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage
Progenics Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase
Progenics Pharmaceuticals, Inc., History
Progenics Pharmaceuticals, Inc., Subsidiaries
Progenics Pharmaceuticals, Inc., Key Competitors
Progenics Pharmaceuticals, Inc., Ratios based on current share price
Progenics Pharmaceuticals, Inc., Annual Ratios
Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Progenics Pharmaceuticals, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Progenics Pharmaceuticals, Inc., Pipeline Products by Therapy Area
Progenics Pharmaceuticals, Inc., Pipeline Products by Development Phase
Progenics Pharmaceuticals, Inc., Performance Chart (2011 - 2015)
Progenics Pharmaceuticals, Inc., Ratio Charts
Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

I would like to order:

Product name: Progenics Pharmaceuticals, Inc. (PGNX) - Financial and Strategic SWOT Analysis Review
Product link: <https://marketpublishers.com/r/P777AF6C943EN.html>
Product ID: P777AF6C943EN
Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/P777AF6C943EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**